Altimmune, Inc.
ALT
$7.03
$0.253.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.12% | -95.31% | -81.36% | 604.94% | 618.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.12% | -95.31% | -81.36% | 604.94% | 618.99% |
| Cost of Revenue | 9.32% | 24.97% | 16.58% | 11.43% | -3.64% |
| Gross Profit | -9.94% | -25.75% | -16.98% | -10.72% | 4.31% |
| SG&A Expenses | 14.43% | 15.60% | 14.75% | 12.31% | 9.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.41% | 22.94% | 16.20% | 11.61% | -1.07% |
| Operating Income | -10.90% | -23.54% | -16.52% | -11.04% | 1.62% |
| Income Before Tax | 1.99% | -7.48% | -31.93% | -24.34% | -8.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.72% | -7.48% | -31.93% | -24.64% | -8.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.72% | -7.48% | -31.93% | -24.64% | -8.68% |
| EBIT | -10.90% | -23.54% | -16.52% | -11.04% | 1.62% |
| EBITDA | -11.30% | -23.98% | -17.29% | -11.50% | 1.42% |
| EPS Basic | 21.09% | 18.58% | -1.24% | 0.53% | 8.41% |
| Normalized Basic EPS | 8.25% | 6.50% | 12.60% | 13.80% | 20.84% |
| EPS Diluted | 21.09% | 18.58% | -0.69% | 1.21% | 9.00% |
| Normalized Diluted EPS | 8.25% | 6.50% | 12.60% | 13.80% | 20.84% |
| Average Basic Shares Outstanding | 23.65% | 33.43% | 32.66% | 26.82% | 18.60% |
| Average Diluted Shares Outstanding | 23.65% | 33.43% | 32.66% | 26.82% | 18.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |